Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL) will participate in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022. Raj Mehra, Ph.D., Chairman and CEO, will conduct virtual 1x1 meetings during the event. This event will feature over 200 innovative biotechnology and life sciences companies, allowing for direct engagement with senior management teams and expert panel discussions. Seelos is focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio including treatments for major depressive disorder and ALS.

NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 11^th Annual LifeSci Partners Corporate Access Event, January 5-7^th, 2022.

Raj Mehra, Ph.D., Chairman and CEO will host 1x1 meetings virtually on Wednesday-Friday, January 5-7^th, 2022.

For information and registration: LifeSci Partners Corporate Access Event 2022

About the 11^th Annual LifeSci Partners Corporate Access Event

The LifeSci Partners 11th Annual Corporate Access Event will feature more than 200 innovative publicly traded and privately held biotechnology, medical technology, pharmaceutical, life sciences, and digital health companies from across the globe.

This event will include 1x1 meetings with company senior management teams and panel discussions featuring KOLs, CEOs, specialized investors, and healthcare experts highlighting the most relevant topics impacting the life sciences industry today.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 2^nd Floor
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/ 
https://twitter.com/seelostx 
https://www.linkedin.com/company/seelos

Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-11th-annual-lifesci-partners-corporate-access-event-301445887.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What is the significance of Seelos Therapeutics' participation in the 11th Annual LifeSci Partners Corporate Access Event?

Seelos Therapeutics' participation signifies its commitment to engage with investors and highlight its innovative therapies aimed at central nervous system disorders and rare diseases.

When will the 11th Annual LifeSci Partners Corporate Access Event take place?

The event will take place from January 5-7, 2022.

Who will represent Seelos Therapeutics at the event?

Raj Mehra, Ph.D., Chairman and CEO, will represent Seelos Therapeutics and host virtual 1x1 meetings.

How many companies will be featured at the LifeSci Partners Corporate Access Event?

More than 200 biotechnology and life sciences companies will be featured at the event.

What are the main focus areas of Seelos Therapeutics?

Seelos Therapeutics focuses on developing therapies for central nervous system disorders and rare diseases, including acute suicidal ideation and ALS.